Peptide Health Lab

Sexual health

Kisspeptin

FOR RESEARCH PURPOSES ONLY

Regulatory status
Research only
Evidence grade
Human RCT evidence

Last reviewed September 1, 2026 · 16 sources

What kisspeptin is and how it works

"Kisspeptin" is a family name, not a molecule. The KISS1 gene encodes a 145-residue precursor that is cleaved to a 54-amino-acid peptide, kisspeptin-54, also called metastin, and truncated further to kisspeptin-14, kisspeptin-13 and the decapeptide kisspeptin-10. All of them share the same C-terminal ten residues and all act at the same receptor, KISS1R, which was called GPR54 before the ligand was identified.[15]

That shared receptor is why the family is discussed as one thing, and it is also the trap. The members are not interchangeable in evidence terms, and the split runs through the middle of this page. The IVF-trigger trials, the hypothalamic amenorrhoea studies and both hypoactive sexual desire disorder trials used kisspeptin-54. The dose-response work in healthy men, the sexual-dimorphism study and the longest administration study used kisspeptin-10 — which is also the only form registered as a bulk ingredient in the United States, and therefore the form a reader is most likely to encounter. When kisspeptin-10 was given to women in the follicular phase of the menstrual cycle at doses far above those that work in men, it did nothing measurable to their gonadotropins.[3] Two peptides that share a receptor are still two peptides, and every result sentence below therefore names which one, by which route, in whom.

Two further boundaries matter. MVT-602, TAK-448 and TAK-683 are synthetic kisspeptin-receptor agonists, not kisspeptin — they are longer-acting, they are dosed in fixed micrograms rather than in nmol per kilogram, and their results belong to them.[14] And the genetics of KISS1 and KISS1R is evidence about the molecule the body makes, not about administering one.[16]

Mechanistically, kisspeptin acts a step upstream of the drugs most readers will have heard of. It stimulates hypothalamic GnRH neurons, which release GnRH, which drives pituitary LH and FSH, which drive the gonads. That extra step costs potency: given head to head by intravenous infusion in healthy men, GnRH produced roughly three-fold higher LH than kisspeptin-10 and roughly two-fold higher than kisspeptin-54.[4]

And the direction of the effect inverts with the pattern of exposure. Acute or intermittent administration stimulates the axis; sustained exposure desensitizes it. This is not a fringe observation — the analog TAK-448 was developed on precisely that basis, as a testosterone-suppressing agent for prostate cancer.[13] More is not more here, and a compound described as a testosterone booster is the same scaffold as a chemical castration programme.

What the research actually shows

Hormone release in healthy adults is the solid part. A 90-minute intravenous kisspeptin-54 infusion at 4 pmol/kg/min in six healthy men raised mean LH to 10.8 ± 1.5 U/litre against 4.2 ± 0.5 on saline (P < 0.001), with FSH and testosterone also rising, and measured the peptide's plasma half-life at 27.6 ± 1.1 minutes.[1] Intravenous kisspeptin-10 boluses in healthy men produced a dose-dependent LH rise peaking at 1 microgram/kg — and a 3 microgram/kg dose produced a smaller response than 1 microgram/kg (P < 0.05), so the curve turns over.[2]

The 2026 chronic-administration trial is the most protocol-relevant study on this page, and it is two-sided. In 15 healthy men with 12 controls, acute subcutaneous kisspeptin-10 infusions raised LH, FSH and testosterone dose-dependently (P < .0001). A continuous five-day infusion at 180 nmol/h left gonadotropin concentrations similar to vehicle — though testosterone remained elevated. An intermittent schedule of eight hours on and sixteen off sustained a gonadotropin rise across twelve days, with the mean LH increase falling from +1.68 ± 0.25 on day 1 to +1.14 ± 0.33 on day 12 (P = .003 against vehicle).[5] The schedule, not the dose, decided whether the compound worked.

The two sexual-desire trials measured brain activity, not desire. Both were randomized, double-blind, placebo-controlled crossovers at one UK centre using intravenous kisspeptin-54 at 1 nmol/kg/h for 75 minutes in people with a diagnosis of hypoactive sexual desire disorder. In the women's trial, 40 were randomized and 32 completed both visits; the primary outcome was blood-oxygen-level-dependent brain response, kisspeptin modulated activity in several regions, and the authors' stated conclusion is that the findings "lay the foundations for clinical applications". Kisspeptin was reported as well-tolerated with no adverse effects.[8] In the men's trial, 37 were randomized and 32 completed; the primary whole-brain endpoint was met, at a mean absolute change of 0.81 (95% CI, 0.41–1.21; P = .003). Penile tumescence rose by up to 56% more than placebo (mean difference 0.28, 95% CI 0.04–0.52; P = .02) and self-reported happiness about sex by 0.63 (95% CI 0.10–1.15; P = .02) — and the paper describes both as secondary analyses.[9]

The IVF-trigger line is the most clinically concrete work in the field. A phase 2 open-label randomized dose-allocation trial gave a single subcutaneous kisspeptin-54 injection to 60 women at high risk of ovarian hyperstimulation syndrome: oocyte maturation occurred in 95%, and no woman developed moderate, severe or critical OHSS. The highest oocyte yield followed the largest dose, but that comparison's confidence interval ran from −16% to 153%, and the trial had no non-kisspeptin comparator arm.[10] A later randomized, placebo-controlled trial in 62 such women met its primary endpoint narrowly — 71% versus 45% reaching an oocyte yield of at least 60%, an absolute difference of 26% (CI 2–50%, P = 0.042) — with the authors writing that further studies are warranted to compare kisspeptin-54 directly against more established triggers.[11]

In hypothalamic amenorrhoea, the acute effect was large and the sustained one was not. Twice-daily subcutaneous kisspeptin-54 in women with the condition produced a first-day LH rise of 24.0 ± 3.5 IU/litre that had fallen to 2.5 ± 2.2 by the fourteenth day (P < 0.05), and no significant change in LH pulsatility or in ultrasound measures of reproductive activity — the downstream endpoints were missed, with five women per group.[6]

The safety picture, as far as it goes, is reassuring for short exposures. In 95 participants — 63 men and 32 women — given a 75-minute intravenous kisspeptin-54 infusion and a rate-matched placebo in random order, LH rose significantly (P < .001), confirming the dose was biologically active, while state anxiety (P = .13), cortisol (P = .73), systolic (P = .74) and diastolic blood pressure (P = .90) and heart rate (P = .52) were all unchanged.[12] A separate study found that a week of twice-daily kisspeptin-54 in healthy women did not abolish menstrual cyclicity, but did shorten the cycle by 1.8 days and advance both the LH peak and the luteal phase by more than two days each, all at P < 0.05.[7]

Where the evidence is weak

This literature comes almost entirely from one research group, and that is the single most important thing to know about it. All sixteen studies cited on this page are human studies, and Waljit Dhillo of Imperial College London is the senior author on eleven of them and the first author on a twelfth; the overlap in the rest of the author lists is heavy. Both hypoactive sexual desire disorder trials, both IVF-trigger trials, the hypothalamic amenorrhoea study, the head-to-head comparison, the sexual-dimorphism study, the menstrual-cyclicity study, the anxiety study, the 2026 chronic-administration study and the MVT-602 analog trials all come from that group.[8][11] Human administration work from elsewhere exists but is thin and points at different questions: the kisspeptin-10 dose-response work in men came from a Medical Research Council unit in Edinburgh,[2] and the KISS1R genetics — the one genuinely multi-centre part of the field — was reported independently by groups in Boston and Paris in 2003.[15][16] A PubMed search for kisspeptin AND (fMRI OR "functional magnetic resonance") on 1 September 2026 returned 11 records, and surfaced no independent replication of the sexual-brain-processing findings: the only two records in that set that administered kisspeptin to humans alongside functional imaging list the same senior author, a third imaging study from the same group was carried out in rodents, and the remainder are genetics reports, observational measurements, or studies of other molecules.

Industry relationships run through the same set of names, and they are disclosed here consistently. The two analog studies are unambiguously industry work: four of the five authors of the TAK-448 paper are at Takeda,[13] and the MVT-602 paper lists Myovant Sciences employees among its authors and declares Myovant consultancy fees for two of the academic authors.[14] The same disclosure applies to several of the academic trials rather than only to the analog ones: the two HSDD trials and the 2026 chronic-administration study each carry declared Myovant consultancy relationships, and the HSDD trials additionally declare an author employed by a commercial contract-research organisation.[8][9][5] None of that invalidates any of the results. It does mean the field's academic and commercial halves are not staffed by different people.

The endpoints are biomarkers. An LH pulse, a testosterone concentration, a brain-activation map and an oocyte-maturation percentage are all measurements taken along the way to an outcome rather than the outcome itself. Where a downstream endpoint was actually measured — LH pulsatility and ultrasound evidence of reproductive activity in hypothalamic amenorrhoea — it did not move.[6]

The trials are very small. Six participants in the foundational infusion study, five per dosing group in the head-to-head comparison, five per arm in the hypothalamic amenorrhoea study, four to five per group in the sexual-dimorphism study. The head-to-head paper names its small sample size as its own limitation.[4][1]

The exposures are short. The longest human administration on this page is twelve days.[5] A PubMed search for kisspeptin AND "long-term safety" on 1 September 2026 returned one record, a review of a different drug class rather than a kisspeptin safety study.

And the claim most readers arrive with is the one the searches come back empty on. A PubMed search for kisspeptin AND (testosterone replacement OR hypogonadism treatment) restricted to the randomized-controlled-trial filter on 1 September 2026 returned no records, and a PubMed search for kisspeptin AND (muscle OR "lean mass" OR "fat loss") limited to human studies and the clinical-trial filter on 1 September 2026 also returned no records. The desire evidence is described above: two randomized trials, both in people with a diagnosis, both with imaging primary endpoints.

On the grade shown at the top of this page. It reads human RCT evidence because that is what exists — ten of the sixteen studies cited here are typed by PubMed as randomized controlled trials, which is far more randomized human work than most compounds in this library carry. It should be read narrowly. Those trials establish that kisspeptin raises gonadotropins and testosterone acutely, that it triggers oocyte maturation in IVF, and that it alters brain responses in diagnosed hypoactive sexual desire disorder. They do not establish an effect on desire in anyone without that diagnosis, on fertility outcomes against an established comparator, on testosterone therapy, or on anything at all beyond twelve days of exposure.

Legal and regulatory status

Searches of Drugs@FDA and the FDA approved-labeling database on 1 September 2026 for kisspeptin, kisspeptin-10, kisspeptin-54 and metastin returned no records on any of them — run alongside same-session semaglutide and somatropin control searches on the same endpoints that returned results normally — so no kisspeptin peptide is approved by the FDA for any indication, in any form, by any route. The National Drug Code directory does return four kisspeptin entries, and reading them row by row is the point: all four are registered as bulk ingredient, product type bulk ingredient, dosage form powder, with no route of administration and no brand name. A bulk-ingredient registration is a record that an active pharmaceutical ingredient is being supplied into the compounding channel. It is not an approval, and there is no approved kisspeptin product behind it.

Kisspeptin-10 is named on FDA's current category 2 list of bulk drug substances, and the precision here matters. On the FDA document titled 503A Bulk Drug Substance Nomination Category Lists, self-dated Updated May 14, 2026, kisspeptin-10 appears exactly once, under the heading 503A Category 2: Bulk Drug Substances that Raise Significant Safety Risks, whose six members are cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine hydrochloride for intrauterine administration. On FDA's separate web page Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, stamped content current as of 04/22/2026, kisspeptin-10 appears in the table headed Bulk drug substances under category 2 of the interim policies — the current table, scoped 503A, date added September 29, 2023 — and not in the separate table headed Bulk drug substances nominated but withdrawn on the same page. Those are two different documents and, on the second of them, two different tables, and conflating them overstates or understates the position depending on which way the error runs.

FDA's stated reason, verbatim from that table, is that compounded drugs containing kisspeptin-10 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization", that the agency "has no, or only limited, safety-related information for the proposed routes of administration", and that "therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans." Read that carefully: FDA is not asserting a demonstrated harm. It is saying it does not know. Kisspeptin is absent from the corresponding 503B outsourcing-facility bulks list, checked with in-document controls. A category 2 listing is a fact about a nomination and a safety concern — not an approval, not a compounding authorization, and not a safety clearance.

Registry position. A ClinicalTrials.gov query for kisspeptin on 1 September 2026 returned 45 studies, of which four are terminated and two withdrawn. Four entries carry a self-declared phase 3 label; those are registry fields on small single-administration studies rather than a phase 3 programme, and this page does not describe one. The registered trials of the analog TAK-448 in hypogonadotropic hypogonadism and in middle-aged and older men with low testosterone are both recorded as terminated, as is its prostate-cancer study.

Anti-doping. Kisspeptin is named on the 2026 WADA International Standard Prohibited List, which came into effect on 1 January 2026, retrieved on 1 September 2026 through the USADA prohibited-list page to the WADA-hosted PDF. The entry is "kisspeptin and its agonist analogues", at S2.2.1, under the heading "Testosterone-stimulating peptides in males including, but not limited to:" — the scope clause in males is part of the heading and is reproduced here as printed. Section S2, Peptide Hormones, Growth Factors, Related Substances, and Mimetics, is prohibited at all times, in- and out-of-competition, and the class header states that all prohibited substances in the class are non-Specified Substances. The class also carries the reach clause that the listed substances "and other substances with similar chemical structure or similar biological effect(s), are prohibited". A full-text search of the 2026 Monitoring Program, retrieved by the same route on 1 September 2026, returned no occurrence of kisspeptin; that document's only peptide-hormone entry names GnRH analogues in females under 18 years only, which does not reach kisspeptin, and monitoring is not prohibition in any case. The List is reissued annually.

Every human study described on this page administered peptide prepared for clinical trial use, by intravenous or subcutaneous infusion in a research unit, under monitoring, with repeated blood sampling — including the 95-participant study that generated most of the safety numbers above.[12] Material sold as "kisspeptin" outside that setting is not the material those trials used, carries no approved labeling, and may be a different member of the family than the one a given result belongs to. PHL does not sell peptides, does not prescribe, and does not tell anyone where to obtain anything.

Questions to bring to a provider

The useful conversation about kisspeptin starts by separating what the trials measured from what a reader wants. Questions worth raising:

  • Which peptide is actually being discussed — kisspeptin-54, kisspeptin-10, or a synthetic analog — and does the evidence being cited belong to that one? Results in this family do not transfer between members.[3]
  • Every human study used intravenous or subcutaneous infusion in a research unit, and the longest exposure anywhere was twelve days. What would that imply about anything longer, given that the response itself changes with the duration of exposure?[5]
  • The desire trials enrolled people with a diagnosis of hypoactive sexual desire disorder and their primary endpoints were brain images. Is low desire the actual problem here, and is it being worked up as one — medication effects, mood, sleep, relationship, or a hormonal cause that has its own tests?[9]
  • The same receptor that raises testosterone acutely was the basis of a testosterone-suppression programme in prostate cancer. Is that two-sided pharmacology understood before anything is considered?[13]
  • For anyone thinking about fertility: the IVF work is a trigger given once in a monitored cycle by a specialist unit, and its own authors called for direct comparison against established triggers. How does that map onto the situation at hand?[11]
  • Given that FDA has said it lacks sufficient information to know whether compounded kisspeptin-10 would cause harm, what is the plan for monitoring, and what would count as a reason to stop?

A compound with real randomized human trials and no established use is an unusual thing to hold in mind. The trials are genuine; they were designed to answer physiological questions, and they answered them. That is a different achievement from showing that anyone is better off.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Stimulation of LH, FSH and testosterone in healthy adults
Human RCT evidence human RCT · human observational

This is the best-established effect and it is genuinely randomized. A 90-minute intravenous kisspeptin-54 infusion in six healthy men raised mean LH to 10.8 against 4.2 U/litre on saline (P less than 0.001), with FSH and testosterone also rising. Intravenous kisspeptin-10 boluses in healthy men produced a dose-dependent LH rise that peaked at 1 microgram/kg, and a 3 microgram/kg dose produced a smaller response than 1 (P less than 0.05), so the dose-response is not monotonic. A 2026 randomized study confirmed dose-dependent rises in LH, FSH and testosterone with acute subcutaneous kisspeptin-10. Every endpoint here is a circulating hormone concentration, which is a biomarker and not a clinical outcome.

[1] [2] [5]

Response depends on the peptide, the sex and the phase of the menstrual cycle
Human RCT evidence human observational

Results do not transfer across the family or across populations. In healthy men, intravenous kisspeptin-10 raised LH at doses as low as 0.3 nmol/kg; in women in the follicular phase, no alterations in gonadotropins were observed after intravenous bolus, subcutaneous bolus or intravenous infusion at maximal doses of 10 nmol/kg, 32 nmol/kg and 720 pmol/kg/min respectively, while the same women responded in the preovulatory phase. Compared head to head in healthy men, kisspeptin-10 and kisspeptin-54 produced similar gonadotropin secretion while GnRH was roughly three times more potent than kisspeptin-10; the authors named the small sample size as their own limitation, at five participants per group.

[3] [4]

Sexual brain processing in people with diagnosed hypoactive sexual desire disorder
Human RCT evidence human RCT

Two randomized, double-blind, placebo-controlled crossover trials at one UK centre administered intravenous kisspeptin-54 at 1 nmol/kg/h for 75 minutes. In women, 40 were randomized and 32 completed both visits, and the primary outcome was blood-oxygen-level-dependent brain activity rather than sexual desire; kisspeptin modulated activity in several regions, and the authors' own framing is that the findings "lay the foundations for clinical applications". In men, 37 were randomized and 32 completed, and the primary whole-brain endpoint was met with a mean absolute change of 0.81 (95% CI, 0.41–1.21; P = .003). The imaging endpoints were met; the endpoints were images.

[8] [9]

Sexual desire or arousal in people without a hypoactive sexual desire disorder diagnosis
Anecdotal reports only human RCT

In the men's HSDD trial the increases in penile tumescence (up to 56% more than placebo; mean difference 0.28, 95% CI 0.04–0.52; P = .02) and in self-reported happiness about sex (mean difference 0.63, 95% CI 0.10–1.15; P = .02) are described by the authors themselves as secondary analyses in a diagnosed population, not as primary endpoints. A PubMed search for kisspeptin AND libido in the title or abstract on 1 September 2026 returned three records, none of them a trial administering kisspeptin with a libido outcome, and a search for kisspeptin AND "sexual desire" in the title or abstract on the same date returned eight, of which the only administration trials are the two HSDD studies above, so no trial with a desire outcome in an undiagnosed population was found by either search.

[9]

Triggering oocyte maturation in IVF
Human RCT evidence human RCT

A phase 2, open-label, randomized dose-allocation trial gave a single subcutaneous kisspeptin-54 injection to 60 women at high risk of ovarian hyperstimulation syndrome; oocyte maturation occurred in 95%, no woman developed moderate, severe or critical OHSS, and the highest oocyte yield followed the largest dose — but that dose comparison's confidence interval ran from −16% to 153% and therefore crossed zero, and the trial had no non-kisspeptin comparator arm. A later randomized, placebo-controlled trial in 62 similar women met its primary endpoint narrowly: 71% against 45% achieved an oocyte yield of at least 60%, an absolute difference of 26% (CI 2–50%, P = 0.042). Those authors wrote that further studies are warranted to compare kisspeptin-54 directly with more established triggers.

[10] [11]

Restoring reproductive hormone secretion in hypothalamic amenorrhoea
Human RCT evidence human RCT

In a randomized parallel-group study, twice-daily subcutaneous kisspeptin-54 for two weeks in women with hypothalamic amenorrhoea potently raised LH and FSH on the first day, and that response had largely disappeared by the fourteenth. The downstream endpoints were missed: no significant changes in LH pulsatility or in ultrasound measures of reproductive activity were observed, with five women per group.

[6]

What the KISS1 and KISS1R genetics establishes — and what it does not
Anecdotal reports only human observational

In 2003 two groups reported independently, one in Boston and one in Paris, that loss-of-function mutations in GPR54 (now KISS1R) cause hypogonadotropic hypogonadism in humans, work carried out in consanguineous families rather than in randomized trials. That establishes that the pathway is required for normal puberty and reproductive function. It is not evidence that administering kisspeptin to someone with an intact pathway does anything, and the two claims are routinely conflated.

[15] [16]

FOR RESEARCH PURPOSES ONLY

Typical protocol range in the research

  • Kisspeptin-54, intravenous infusion, in six healthy men in a double-blind placebo-controlled crossover physiology study; figure from the abstract

    4 pmol/kg per minute for 90 minutes [1]

  • Kisspeptin-54, intravenous infusion, the rate used in the two hypoactive sexual desire disorder trials and in the largest single safety dataset — 32 women and 32 men who completed the two crossover trials, and 95 participants in the anxiety study; figures from the abstracts

    1 nmol/kg per hour for 75 minutes [8] [9] [12]

  • Kisspeptin-10 and kisspeptin-54 compared head to head against GnRH by intravenous infusion in healthy men, five participants per dosing group, three hours per infusion; figures from the abstract

    0.1, 0.3 and 1.0 nmol/kg per hour [4]

  • Kisspeptin-10, subcutaneous infusion, in a randomized single-blinded placebo-controlled study of 15 healthy men with 12 controls; the three schedules are separate arms and are not interchangeable; figures from the abstract

    An acute eight-hour dose-response infusion at 1.25 to 10.0 nmol/kg per hour; a continuous infusion at 180 nmol per hour for five days; and a daily eight-hours-on, sixteen-hours-off infusion at 150 nmol per hour for twelve days [5]

  • Kisspeptin-54, single subcutaneous injection as an oocyte-maturation trigger 36 hours before retrieval, in 60 women at high risk of ovarian hyperstimulation syndrome undergoing IVF; and a second injection ten hours after the first in a later randomized trial of 62 such women; figures from the abstracts

    3.2 to 12.8 nmol/kg as a single trigger injection; 9.6 nmol/kg repeated once at ten hours in the second-dose trial [10] [11]

  • MVT-602, which is a synthetic kisspeptin-receptor agonist and a different molecule from kisspeptin-10 or kisspeptin-54, given as a single subcutaneous dose to 24 healthy premenopausal women in a phase 1 trial and 75 in a phase 2a trial; note the units are fixed micrograms rather than nmol/kg; figures from the abstract

    0.1, 0.3, 1.0 or 3.0 micrograms as a single subcutaneous dose [14]

Every figure above was administered by intravenous or subcutaneous infusion or injection in a hospital research unit, under monitoring, for periods measured in minutes to a maximum of twelve days. The units are not interchangeable across the family: kisspeptin-54 and kisspeptin-10 are dosed in pmol or nmol per kilogram, MVT-602 in fixed micrograms, and a figure for one is not a figure for another. A PubMed search for kisspeptin AND self-administration on 1 September 2026 returned three records, none of them about human self-administration of kisspeptin, and a PubMed search for kisspeptin AND "home administration" on 1 September 2026 returned no records, so neither search located an administered amount established for any use outside a trial. Ranges here are what published research reports.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

  • Loss of response with repeated or continuous exposure (tachyphylaxis)

    In ten women with hypothalamic amenorrhoea given twice-daily subcutaneous kisspeptin-54 or saline for two weeks, the maximum rise in LH within four hours of injection fell from 24.0 plus or minus 3.5 IU/litre on the first day to 2.5 plus or minus 2.2 IU/litre on the fourteenth, and FSH from 9.1 to 0.5, both P less than 0.05 · This is the central pharmacological limit of the compound rather than a side effect in the usual sense, and it runs directly against the intuition that more or longer is better. A later randomized study in healthy men found the same direction of travel by a different route: a continuous five-day subcutaneous kisspeptin-10 infusion left gonadotropin concentrations similar to vehicle, while an intermittent schedule of eight hours on and sixteen off sustained a smaller rise across twelve days. Both halves belong on the record — the continuous arm of that study did keep testosterone elevated even while gonadotropins were not.

    [6] [5]

  • Testosterone driven below the castration range by sustained exposure to the kisspeptin analog TAK-448

    In a phase 1 programme in which 82 healthy men received TAK-448 and 30 received placebo, a 14-day subcutaneous infusion at doses above 0.1 mg/day dropped testosterone below baseline by 60 hours and to a sustained below-castration level by day 8; in prostate-cancer patients given 12 or 24 mg depot injections, testosterone fell below 20 ng/dL in four of five · TAK-448 is a synthetic analog and not kisspeptin-10 or kisspeptin-54, so this is the analog's finding and not a measured result for either native peptide. It is on this page because it establishes the direction of the effect at the receptor under sustained exposure: the same target that raises testosterone when stimulated acutely was the basis of a programme designed to suppress testosterone in prostate cancer. Anyone reading about kisspeptin as something that raises testosterone is reading about one half of a two-sided pharmacology.

    [13]

  • Shift in menstrual-cycle timing

    In ten healthy women given twice-daily subcutaneous kisspeptin-54 or saline on menstrual days 7 to 14, mean cycle length was 26.8 plus or minus 3.1 days on kisspeptin against 28.6 plus or minus 1.4 on saline (P less than 0.01), the day of highest LH moved from 15.2 to 13.0 (P less than 0.05) and the day of the progesterone rise from 18.0 to 15.8 (P less than 0.05) · Cyclicity persisted in every woman and the authors' conclusion was that a week of exposure does not abolish it, so this is a measurable timing shift rather than a disruption. It is reported here because it is a real, statistically significant physiological effect in healthy people at a dose used across this literature, in a study PubMed types as a controlled clinical trial rather than a randomized one.

    [7]

  • Adverse events in the analog programmes

    Grade 1 to 2 adverse events were reported in 26% of subjects during TAK-448 treatment in the phase 1 programme; MVT-602 was reported as safe and well tolerated across its entire dose range in both of its randomized placebo-controlled trials · Both figures come from short exposures in screened volunteers under supervision, and neither is a long-term safety dataset. The whole indexed human adverse-event literature for kisspeptin and its analogs is small: a PubMed search for kisspeptin AND "adverse events" limited to human studies on 1 September 2026 returned four records.

    [13] [14]

  • Anxiety, cortisol, blood pressure and heart rate — measured and not significantly changed

    In 95 participants (63 men, 32 women) given a 75-minute intravenous kisspeptin-54 infusion and rate-matched placebo in random order, state anxiety was not significantly altered (P = .13) and there was no significant effect on cortisol (P = .73), systolic (P = .74) or diastolic blood pressure (P = .90), or heart rate (P = .52), while LH rose significantly (P less than .001), confirming the dose was biologically active · This is the counterweight to the entries above and the largest single human kisspeptin dataset on this page. It is a null result on pre-specified measures at one dose over 75 minutes in screened volunteers, which is meaningfully reassuring for that exposure and says nothing about any longer one.

    [12]

  • Effects of exposure beyond twelve days

    not established · The longest continuous or repeated human administration identified anywhere in the literature cited on this page is twelve days, in 15 healthy men. A PubMed search for kisspeptin AND "long-term safety" on 1 September 2026 returned one record, which is a review of a different drug class rather than a kisspeptin safety study. Absence of a signal over days is not evidence about months, and a compound whose defining pharmacological feature is that the response changes with the duration of exposure is one where that gap matters more than usual.

    [5]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage
Kisspeptin peptides are supplied as freeze-dried powder, and the four kisspeptin-10 entries in the US National Drug Code directory are all registered as bulk ingredient, powder, with no route of administration and no brand name attached. Because no FDA-approved kisspeptin product exists, there is no approved labeling that states a storage condition for any kisspeptin preparation, so the answer here is peptide convention rather than a regulated fact: lyophilized research peptides are conventionally kept frozen or refrigerated and protected from light and moisture. The published human studies used peptide prepared for clinical trial use in a hospital setting, and this page reports no stability data for material held under any other conditions.
Reconstituted storage
Once in solution a research peptide is conventionally refrigerated, protected from light, and treated as short-dated. Because no kisspeptin product is FDA-approved, no approved labeling states an in-use period for any kisspeptin preparation, and none is given here. Kisspeptin-54's measured plasma half-life of roughly 28 minutes describes how fast the peptide disappears from the bloodstream, not how long a solution of it lasts, and the two are routinely confused.
Reconstitution diluent
Bacteriostatic water, which is sterile water containing 0.9% benzyl alcohol, is the conventional diluent for lyophilized research peptides and is the default answer for kisspeptin. No approved kisspeptin labeling exists to specify a diluent, so this is convention and not a regulated instruction.
Reconstitution & handling
Handling conventions only: add the diluent slowly down the vial wall rather than directly onto the powder, swirl gently rather than shake, allow the powder to dissolve fully before assessing the solution, keep the stopper sanitized, and discard anything cloudy or particulate. FDA's own stated concern about compounded kisspeptin-10 is immunogenicity risk for certain routes of administration together with complexities around peptide-related impurities and characterization of the active ingredient, and no handling convention addresses either of those.
Handling notes
The trials described on this page administered kisspeptin by intravenous infusion or subcutaneous injection in a hospital research unit with monitoring and repeated blood sampling. Nothing about the storage conventions above changes that, and none of the published safety data was generated with material handled outside that setting.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

16 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder